- Home
- HUBC vs EVAX Comparison
HUBC vs EVAX Comparison
Compare HUBC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBC
- EVAX
- Stock Information
- Founded
- HUBC 2017
- EVAX 2008
- Country
- HUBC Israel
- EVAX Denmark
- Employees
- HUBC N/A
- EVAX N/A
- Industry
- HUBC
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUBC
- EVAX Health Care
- Exchange
- HUBC Nasdaq
- EVAX Nasdaq
- Market Cap
- HUBC N/A
- EVAX 16.3M
- IPO Year
- HUBC N/A
- EVAX 2021
- Fundamental
- Price
- HUBC $3.14
- EVAX $1.64
- Analyst Decision
- HUBC
- EVAX Strong Buy
- Analyst Count
- HUBC 0
- EVAX 2
- Target Price
- HUBC N/A
- EVAX $10.00
- AVG Volume (30 Days)
- HUBC 155.1K
- EVAX 65.8K
- Earning Date
- HUBC 12-13-2024
- EVAX 05-27-2025
- Dividend Yield
- HUBC N/A
- EVAX N/A
- EPS Growth
- HUBC N/A
- EVAX N/A
- EPS
- HUBC N/A
- EVAX N/A
- Revenue
- HUBC $33,357,000.00
- EVAX $3,344,000.00
- Revenue This Year
- HUBC N/A
- EVAX $102.45
- Revenue Next Year
- HUBC N/A
- EVAX $200.44
- P/E Ratio
- HUBC N/A
- EVAX N/A
- Revenue Growth
- HUBC N/A
- EVAX 4480.82
- 52 Week Low
- HUBC $2.65
- EVAX $1.61
- 52 Week High
- HUBC $21.70
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- HUBC 35.15
- EVAX 33.33
- Support Level
- HUBC $2.65
- EVAX $1.67
- Resistance Level
- HUBC $3.72
- EVAX $1.97
- Average True Range (ATR)
- HUBC 0.74
- EVAX 0.11
- MACD
- HUBC -0.11
- EVAX 0.03
- Stochastic Oscillator
- HUBC 12.97
- EVAX 6.02
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.